2026 Global: Cell And Gene Therapy Manufacturing Services Market-Competitive Review (2032) report
Description
The 2026 Global: Cell And Gene Therapy Manufacturing Services Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cell and gene therapy manufacturing services market by geography and historical trend. The scope of the report extends to sizing of the cell and gene therapy manufacturing services market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Ten major companies driving the Cell and Gene Therapy Manufacturing Services market include Lonza, Thermo Fisher Scientific, Charles River Laboratories, Catalent, Merck KGaA (MilliporeSigma), Samsung Biologics, Fujifilm (FUJIFILM Irvine Scientific/Fujifilm Diosynth), AGC Biologics, Oxford Biomedica, and National Resilience (Resilience). These firms lead through a mix of end‑to‑end CDMO capabilities, commercial‑scale cGMP capacity, and specialized platforms for viral vectors, plasmid DNA, and cell therapy automation; Lonza is recognized for broad CDMO infrastructure and commercial manufacturing partnerships; Thermo Fisher combines analytics, consumables, and large‑scale manufacturing services to serve both gene and cell therapy programs; Charles River expanded into cell and gene services via acquisitions and plasmid supply platforms to support upstream development and GMP production; Catalent offers integrated development and commercial biologics manufacturing with increasing ATMP focus; Merck KGaA (MilliporeSigma) supplies critical reagents, single‑use systems, and contract manufacturing expertise that underpin many CGT processes; Samsung Biologics has invested in cell and gene capacities to capture outsourcing demand for later‑stage and commercial production; FUJIFILM provides viral vector and plasmid services through its biologics and contract manufacturing divisions and supports scalable process transfer; AGC Biologics operates multiple global facilities tailored to ATMPs and has pursued acquisitions to expand end‑to‑end capabilities in cell therapy; Oxford Biomedica is a specialty viral‑vector CDMO with deep experience in lentiviral manufacturing and long‑standing partnerships with gene therapy developers; Resilience (National Resilience) develops modular automated manufacturing platforms and networked facilities intended to accelerate scale‑out and commercial supply for complex cellular medicines.
Across these providers, differentiation arises from platform specialization, geographic footprint, and service scope: companies such as Oxford Biomedica and Fujifilm emphasize vector production and plasmid/vector supply chains to meet demand for AAV and lentiviral therapeutics; Lonza, Samsung Biologics, and Catalent position themselves for commercial‑scale biologics and CGT rollouts with large cGMP suites and multi‑site redundancy; Thermo Fisher and Merck couple consumables and analytical QC solutions with CDMO services to offer integrated supply‑chain solutions critical for regulatory filings and batch release; AGC Biologics and Charles River focus on flexible CDMO models that serve early‑ to late‑stage developers and academic spinouts via process development, clinical GMP, and plasmid manufacturing; Resilience and newer platform companies emphasize automation and modularization aimed at reducing per‑patient cost and enabling decentralized manufacturing models.
Investment and strategic activity continue to reshape the competitive landscape: firms are expanding capacity, forming alliances, and acquiring niche providers to fill gaps in vector, plasmid, and automated cell‑therapy workflows, while regional growth—particularly in North America and Asia‑Pacific—drives demand for localized GMP capacity and regulatory support. Market reports and industry trackers consistently list these ten companies among top CGT manufacturing service providers based on capacity, vertical integration, recent investments, and client pipelines, reflecting the sector’s shift from trial‑scale production toward repeatable, commercial supply chains for advanced therapies.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cell and gene therapy manufacturing services market by geography and historical trend. The scope of the report extends to sizing of the cell and gene therapy manufacturing services market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Ten major companies driving the Cell and Gene Therapy Manufacturing Services market include Lonza, Thermo Fisher Scientific, Charles River Laboratories, Catalent, Merck KGaA (MilliporeSigma), Samsung Biologics, Fujifilm (FUJIFILM Irvine Scientific/Fujifilm Diosynth), AGC Biologics, Oxford Biomedica, and National Resilience (Resilience). These firms lead through a mix of end‑to‑end CDMO capabilities, commercial‑scale cGMP capacity, and specialized platforms for viral vectors, plasmid DNA, and cell therapy automation; Lonza is recognized for broad CDMO infrastructure and commercial manufacturing partnerships; Thermo Fisher combines analytics, consumables, and large‑scale manufacturing services to serve both gene and cell therapy programs; Charles River expanded into cell and gene services via acquisitions and plasmid supply platforms to support upstream development and GMP production; Catalent offers integrated development and commercial biologics manufacturing with increasing ATMP focus; Merck KGaA (MilliporeSigma) supplies critical reagents, single‑use systems, and contract manufacturing expertise that underpin many CGT processes; Samsung Biologics has invested in cell and gene capacities to capture outsourcing demand for later‑stage and commercial production; FUJIFILM provides viral vector and plasmid services through its biologics and contract manufacturing divisions and supports scalable process transfer; AGC Biologics operates multiple global facilities tailored to ATMPs and has pursued acquisitions to expand end‑to‑end capabilities in cell therapy; Oxford Biomedica is a specialty viral‑vector CDMO with deep experience in lentiviral manufacturing and long‑standing partnerships with gene therapy developers; Resilience (National Resilience) develops modular automated manufacturing platforms and networked facilities intended to accelerate scale‑out and commercial supply for complex cellular medicines.
Across these providers, differentiation arises from platform specialization, geographic footprint, and service scope: companies such as Oxford Biomedica and Fujifilm emphasize vector production and plasmid/vector supply chains to meet demand for AAV and lentiviral therapeutics; Lonza, Samsung Biologics, and Catalent position themselves for commercial‑scale biologics and CGT rollouts with large cGMP suites and multi‑site redundancy; Thermo Fisher and Merck couple consumables and analytical QC solutions with CDMO services to offer integrated supply‑chain solutions critical for regulatory filings and batch release; AGC Biologics and Charles River focus on flexible CDMO models that serve early‑ to late‑stage developers and academic spinouts via process development, clinical GMP, and plasmid manufacturing; Resilience and newer platform companies emphasize automation and modularization aimed at reducing per‑patient cost and enabling decentralized manufacturing models.
Investment and strategic activity continue to reshape the competitive landscape: firms are expanding capacity, forming alliances, and acquiring niche providers to fill gaps in vector, plasmid, and automated cell‑therapy workflows, while regional growth—particularly in North America and Asia‑Pacific—drives demand for localized GMP capacity and regulatory support. Market reports and industry trackers consistently list these ten companies among top CGT manufacturing service providers based on capacity, vertical integration, recent investments, and client pipelines, reflecting the sector’s shift from trial‑scale production toward repeatable, commercial supply chains for advanced therapies.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.